Causal assessment of surrogacy in a meta-analysis of colorectal cancer trials

Biostatistics

Volumn 12, Issue 3, 2011, Pages 478-492

  Li, Yun ^a   Taylor, Jeremy M G ^b   Elliott, Michael R ^b   Sargent, Daniel J ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Bayesian estimation; Counterfactual model; Identifiability; Multiple trials; Principal stratification; Surrogate marker

Indexed keywords

TUMOR MARKER;

ARTICLE; BAYES THEOREM; CHEMISTRY; CLINICAL TRIAL (TOPIC); COLORECTAL TUMOR; COMPUTER SIMULATION; HUMAN; META ANALYSIS (TOPIC); METHODOLOGY; STATISTICAL MODEL;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; HUMANS; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; TUMOR MARKERS, BIOLOGICAL;

EID: 79959383485     PISSN: 14654644     EISSN: 14684357     Source Type: Journal    
DOI: 10.1093/biostatistics/kxq082     Document Type: Article

References (23)

1. ALONSO, A. AND MOLENBERGHS, G. (2007). Surrogate marker evaluation from an information theory perspective. Biometrics 1, 180-186.
2. ALONSO, A. AND MOLENBERGHS, G. (2008). Evaluating time to cancer recurrence as a surrogate marker for survival from an information theory perspective. Statistical Methods in Medical Research 17, 497-504.
3. BAKER, S. G. (2008). Two simple approaches for validating a binary surrogate endpoint using data from multiple trials. Statistical Methodsin Medical Research 17, 505-514.
4. BUYSE, M. AND MOLENBERGHS, G. (1998). Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics 54, 1014-1029. (Pubitemid 28429294)
5. BUYSE, M., MOLENBERGHS, G., BURZYKOWSKI, T., RENARD, D. AND GEYS, H. (2000). The validation of surrogate endpoints in meta-analyses ofrandomized experiments. Biostatistics 1, 49-67.
6. CELEUX, G., FORBES, F., ROBERT, C. P. AND TITTERINGTON, D. M. (2006). Deviance information criteria for missing data models. Bayesian Analysis 1, 651-674.
7. DANIELS, M. J. AND HUGHES, M. D. (1997). Meta-analysis for the evaluation of potential surrogate markers. Statistics in Medicine 16, 1965-1982. (Pubitemid 27397267)
8. FRANGAKIS, C. E. AND RUBIN, D. B. (2002). Principal stratifcation in casual inference. Biometrics 58, 21-29.
9. FREEDMAN, L. S., GRAUBARD, B. I. AND SCHATZKIN, A. (1992). Statistical validation ofintermediate endpoints for chronic disease. Statistics in Medicine 11, 167-178.
10. GARRET, E. S. AND ZEGER, S. L (2000). Latent class model diagnosis. Biometrics 56, 1055-1067.
11. GILBERT, P. B. AND HUDGENS, M. G. (2008). Evaluating causal effect predictiveness of candidate surrogate endpoints. Biometrics 65, 1223-1232.
12. GUSTAFSON, P. (2005). On model expansion, model contraction, identifability, and prior information: two illustrative scenarios involving mismeasured variables. Statistical Science 20, 111-140. (Pubitemid 41305190)
13. JOFFE, M. M. AND GREENE, T. (2009). Related causal frameworks for surrogate outcomes. Biometrics 65, 530-538.
14. JOFFE, M. M., SMALL, D. AND HSU, C. (2007). Defning and estimating intervention effects for groups that will develop an auxiliary outcome. Statistical Science 22, 74-97.
15. LI, Y., TAYLOR, J. M. G. AND ELLIOTT, M. R. (2010). A Bayesian approach to surrogacy assessment using princi-pal stratifcation in clinical trials. Biometrics 66, 523-531.
16. PRENTICE, R. L. (1989). Surrogate endpoints in clinical trials, defnition and operational criteria. Statistics in Medicine 8,431-440. (Pubitemid 19105891)
17. RUBIN, D. B. (1978). Bayesian-inference for causal effects\role ofrandomization. The Annals of Statistics 6, 34-58.
18. RUBIN, D. B. (1980). Randomization analysis of experimental-data-the Fisher randomization test\comment. Journal of American Statistical Association 75, 591-593.
19. SARGENT, D. J., PATIYIL, S., YOTHERS, G. andothers (2007). End points for colon cancer adjuvant trials: obser-vations and recommendations based on individual patient data from 20 898 patients enrolled onto 18 randomized trials from the ACCENT Group. Journal of Clinical Oncolology 25, 4569-4574. (Pubitemid 350035314)
20. SARGENT, D. J., WIEAND, H. S., HALLER, D. G., andothers (2005). Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20 898 patients on 18 randomized trials. Journal of Clinical Oncolology 23, 8664-8670. (Pubitemid 46211509)
21. TAYLOR, J. M. G., WANG, Y. AND THIÉBAUT, R. (2005). Counterfactual links to the proportion oftreatment effect explained by a surrogate marker. Biometrics 61, 1102-1111. (Pubitemid 43906918)
22. TILAHUN, A., PRYSELEY, A., ALONSO, A. and others (2008). Information theory-based surrogate marker eval-uation from several randomized clinical trials with binary endpoints, using SAS. Journal of Biopharmaceutical Statistics 18, 326-341. (Pubitemid 351355150)
23. WOLFSON, J. AND GILBERT, P. (2010). Statistical Identifability and the Surrogate Endpoint Problem, with Appli-cation to Vaccine Trials. Biometrics 66, 1153-1161.